September 30, 2025

Table 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

Adverse events of grade 2 or higher occurred in over 5% of patients receiving palbociclib and binimetinib.
The combination of binimetinib and palbociclib is studied in patients with advanced triple-negative breast cancer.
The study highlights significant adverse events, prompting attention to patient safety and treatment management.
Ongoing evaluation of adverse effects is critical for understanding the safety profile of these treatments.

Implication

Phase IB trial reports adverse events in patients with triple-negative breast cancer, suggesting careful monitoring.

Adverse events grade 2 or higher attributed to palbociclib and binimetinib (>5% of the patients).

No takes yet. Share an insight, caveat, or question.

Manso et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase IB trial reports adverse events in patients with triple-negative breast cancer, suggesting careful monitoring.

Adverse events grade 2 or higher attributed to palbociclib and binimetinib (>5% of the patients).